Information Provided By: 
Fly News Breaks for October 10, 2016
MRK, INCY
Oct 10, 2016 | 08:52 EDT
After reviewing recent data, JMP Securities analyst Liisa Bayko says that the combination of Incyte's (INCY) Epacadostat plus Merck's (MRK) Keytruda is "emerging as a promising treatment, potentially even best in class." The analyst says that the progression free survival rate of the combination in melanoma patients "is emerging to be quite competitive," while the efficacy rate in other solid tumors "seemed encouraging." The analyst raised her price target on Incyte to $110 from $100 and keeps an Outperform rating on the stock.
News For INCY;MRK From the Last 2 Days
There are no results for your query INCY;MRK
